SCHEMBL14022293

SCHEMBL14022293

COCCCNC(=O)c1ccnc2[nH]c(-c3ccc(CN4CCOCC4)c(F)c3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.40
JAK2 O60674 2/20 0.40
JAK1 P23458 2/20 0.40
TYK2 P29597 2/20 0.40
JAK3 P52333 2/20 0.40
CD274 Q9NZQ7 1/20 0.40
GSK3B P49841 1/20 0.39
BDKRB1 P46663 1/20 0.39
ERCC1 P07992 1/20 0.39
FEN1 P39748 1/20 0.39
ERCC4 Q92889 1/20 0.39
BTK Q06187 2/20 0.39
KMT2A Q03164 1/20 0.39
DHODH Q02127 1/20 0.39
PDE4B Q07343 1/20 0.38
MOK Q9UQ07 1/20 0.38
LMNA P02545 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
FGFR3 P22607 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4905657 0.99 EGLN1 (0.40) EGLN1JAK2JAK1TYK2JAK3
SCHEMBL14022300 0.91 PDE3B (0.42) GSK3BERCC1FEN1ERCC4BTK
SCHEMBL14022298 0.91 LRRK2 (0.46) JAK2JAK3ERCC1FEN1ERCC4
Hydrochloric Acid SCHEMBL4909890 0.90 PDE3B (0.42) GSK3BERCC1FEN1ERCC4BTK
Hydrochloric Acid SCHEMBL4900632 0.90 LRRK2 (0.45) JAK2JAK3ERCC1FEN1ERCC4
SCHEMBL3632162 0.87 ERCC1 (0.51) JAK2JAK3GSK3BERCC1FEN1
Hydrochloric Acid SCHEMBL3635395 0.86 ERCC1 (0.51) JAK2JAK3GSK3BERCC1FEN1
SCHEMBL14022310 0.86 PARP1 (0.53) ERCC1FEN1ERCC4KMT2A
Hydrochloric Acid SCHEMBL4908440 0.85 PARP1 (0.52) ERCC1FEN1ERCC4KMT2A
SCHEMBL14022291 0.81 HRH3 (0.47) CD274GSK3BBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 US disclosed
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders GSK3B, PYGB, GSK3A EGLN1 3334/4885JAK2 418/4885JAK1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.